Bibliography
- Available from: http://www.Drugabuse.Gov/publications/media-guide/science-drug-abuse-addiction
- Available from: http://www.Drugabuse.Gov/publications/addiction-science-molecules-to-managed-care/introduction/drug-abuse-costs-united-states-economy-hundreds-billions-dollars-in-increased-health
- Available from: http://www.Drugabuse.Gov/drugs-abuse/commonly-abused-drugs/commonly-abused-drugs-chart
- Fulton BS. Medication development for the treatment of substance abuse. In: Annual reports in medicinal chemistry. volume 43. Elsevier, Amsterdam; 2008. p. 61-72
- Kenna GA, Nielsen DM, Mello P, et al. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs 2007;21(3):213-37
- Julien RM. A primer of drug action: a concise, nontechnical guide to the actions, uses, and side effects of psychoactive drugs. Worth Publishers, New York; 2001
- Harwood HJ, Myers TG. New treatments for addiction: behavioral, ethical, legal, and social questions. National Academies Press, Washington, DC, USA; 2004
- Rapaka RS, Sadée W. Drug addiction: from basic research to therapy. Springer; AAPS Press, New York, NY; 2008
- Charney DS, Nestler EJ, Sklar P, Buxbaum JD. Neurobiology of mental illness. Oxford University Press, New York, NY; 2013
- Acri JB, Skolnick P. Pharmacotherapy of substance use disorders. In: Charney DS, Nestler EJ, Sklar P, Buxbaum JD, editors. Neurobiology of mental illness. 4th edition. Oxford University Press, London; 2013
- Suvarna V. Phase iv of drug development. Perspect Clin Res 2010;1(2):57-60
- Available from: http://www.Forbes.Com/sites/davidkroll/2013/05/11/why-does-arenas-obesity-drug-have-abuse-potential/
- Shram MJ, Schoedel KA, Bartlett C, et al. Evaluation of the abuse potential of lorcaserin, a serotonin 2c (5-ht2c) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther 2011;89(5):683-92
- Heger M. State challenges to painkiller could threaten fda authority. Nat Med 2014;20(5):453-3
- Available from: http://www.thefix.com/content/inside-addiction-drug-pipeline-vaccines-Scripps8242?page=all
- Macarron R, Banks MN, Bojanic D, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 2011;10(3):188-95
- Forray A, Sofuoglu M. Future pharmacological treatments for substance use disorders. Br J Clin Pharmacol 2014;77(2):382-400
- Volkow ND, Wang GJ, Fowler JS, et al. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci USA 2011;108(37):15037-42
- Volkow ND, Skolnick P. New medications for substance use disorders: challenges and opportunities. Neuropsychopharmacology 2012;37(1):290-2
- Ruiz P, Strain EC, Langrod J. The substance abuse handbook. Lippincott Williams & Wilkins, Philadelhia, PA; 2007
- Lowinson JH. Substance abuse: a comprehensive textbook. Lippincott Williams & Wilkins, Philadelhia, PA; 2005
- Nestler EJ, Malenka RC. The addicted brain. Sci Am 2004;290(3):78-85
- Available from: http://www.Drugabuse.Gov/publications/drugfacts/treatment-approaches-drug-addiction
- Volkow ND, Baler RD. Addiction science: uncovering neurobiological complexity. Neuropharmacology 2014;76(Pt B):235-49
- Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 2006;103(31):11473-8
- Montoya ID. Advances in the development of biologics to treat drug addictions and overdose. Adicciones 2012;24(2):95-103
- Kinsey B. Vaccines against drugs of abuse: where are we now? Ther Adv Vaccin 2014;2(4):106-17
- Michael S, Auld D, Klumpp C, et al. A robotic platform for quantitative high-throughput screening. Assay Drug Dev Technol 2008;6(5):637-57
- Seethala R, Zhang L. Handbook of drug screening. Informa Healthcare, New York; 2009
- Yasgar A, Shinn P, Jadhav A, et al. Compound management for quantitative high-throughput screening. JALA Charlottesv Va 2008;13(2):79-89
- Jin G, Wong ST. Toward better drug repositioning: Prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 2014;19(5):637-44
- Enna SJ, Williams M. Challenges in the search for drugs to treat central nervous system disorders. J Pharmacol Exp Ther 2009;329(2):404-11
- Xie XQ, Wang L, Liu H, et al. Chemogenomics knowledgebased polypharmacology analyses of drug abuse related g-protein coupled receptors and their ligands. Front Pharmacol 2014;5(3):1-11
- Law P-Y. Opioid receptor signal transduction mechanisms. In: The opiate receptors. Springer, New York, NY; 2011. p. 195-238
- Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 2012;31(3):207-25
- White KL, Scopton AP, Rives ML, et al. Identification of novel functionally selective kappa-opioid receptor scaffolds. Mol Pharmacol 2014;85(1):83-90
- Zhou L, Lovell KM, Frankowski KJ, et al. Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem 2013;288(51):36703-16
- Higgins GA, Sellers EM, Fletcher PJ. From obesity to substance abuse: therapeutic opportunities for 5-ht2c receptor agonists. Trends Pharmacol Sci 2013;34(10):560-70
- Cornelius P, Lee E, Lin W, et al. Design, synthesis, and pharmacology of fluorescently labeled analogs of serotonin: application to screening of the 5-ht2c receptor. J Biomol Screen 2009;14(4):360-70
- Jorgensen S, Nielsen EO, Peters D, Dyhring T. Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity. J Neurosci Methods 2008;169(1):168-76
- Picciotto MR. An indirect resilience to addiction. Nat Neurosci 2013;16(5):521-3
- Xiao J, Free RB, Barnaeva E, et al. Discovery, optimization, and characterization of a novel series of dopamine d2 versus d3 receptor selective antagonists. In: Probe reports from the nih molecular libraries program. National Institutes of Health, Bethesda, MD; 2010
- Xiao J, Free RB, Barnaeva E, et al. Discovery, optimization, and characterization of novel d2 dopamine receptor selective antagonists. J Med Chem 2014;57(8):3450-63
- Conley JM, Brust TF, Xu R, et al. Drug-induced sensitization of adenylyl cyclase: assay streamlining and miniaturization for small molecule and sirna screening applications. J Vis Exp 2014;83:e51218
- Weaver CD, Sheffler DJ, Lewis LM, et al. Discovery and development of a potent and highly selective small molecule muscarinic acetylcholine receptor subtype i (machr 1 or m1) antagonist in vitro and in vivo probe. Curr Top Med Chem 2009;9(13):1217-26
- Jakubik J, Santruckova E, Randakova A, et al. Outline of therapeutic interventions with muscarinic receptor-mediated transmission. Physiol Res 2014;63(Suppl 1):S177-89
- Raffa RB. The m-5 muscarinic receptor as possible target for treatment of drug abuse. J Clin Pharm Ther 2009;34(6):623-9
- Gentry PR, Kokubo M, Bridges TM, et al. Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (machr)-selective m -orthosteric antagonist, vu0488130 (ml381): a novel molecular probe. ChemMedChem 2014;9
- Gentry PR, Kokubo M, Bridges TM, et al. Discovery of the first m5-selective and cns penetrant negative allosteric modulator (nam) of a muscarinic acetylcholine receptor: (s)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1h-imidazo[2,1-a]isoindol-5(9bh)-one (ml375). J Med Chem 2013;56(22):9351-5
- Emmitte KA. Recent advances in the design and development of novel negative allosteric modulators of mglu(5). ACS Chem Neurosci 2011;2(8):411-32
- Amato RJ, Felts AS, Rodriguez AL, et al. Substituted 1-phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mglu5: discovery of a new tool compound vu0463841 with activity in rat models of cocaine addiction. ACS Chem Neurosci 2013;4(8):1217-28
- Hu G, Henke A, Karpowicz RJ. Jr, Sonders MS, Farrimond F, Edwards R, Sulzer D, Sames D. New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (vmat2). ACS Chem Biol 2013;8(9):1947-54
- Hershberger PM, Hedrick MP, Peddibhotla S, et al. Imidazole-derived agonists for the neurotensin 1 receptor. Bioorg Med Chem Lett 2014;24(1):262-7
- Peddibhotla S, Hedrick MP, Hershberger P, et al. Discovery of ml314, a brain penetrant non-peptidic beta-arrestin biased agonist of the neurotensin ntr1 receptor. ACS Med Chem Lett 2013;4(9):846-51
- Nagisa S, Toru K, Kazutaka I. Role of girk channels in addictive substance effects. J Drug Alcohol Res 2013;2(2013):1-11
- Lujan R, de Velasco EMF, Aguado C, Wickman K. New insights into the therapeutic potential of girk channels. Trends Neurosci 2014;37(1):20-38
- Kaufmann K, Romaine I, Days E, et al. Ml297 (vu0456810), the first potent and selective activator of the girk potassium channel, displays antiepileptic properties in mice. ACS Chem Neurosci 2013;4(9):1278-86
- Kotsikorou E, Sharir H, Shore DM, et al. Identification of the gpr55 antagonist binding site using a novel set of high-potency gpr55 selective ligands. Biochemistry 2013;52(52):9456-69
- Roman DL, Traynor JR. Regulators of g protein signaling (rgs) proteins as drug targets: modulating g-protein-coupled receptor (gpcr) signal transduction miniperspective. J Med Chem 2011;54(21):7433-40
- Storaska AJ, Mei JP, Wu M, et al. Reversible inhibitors of regulators of g-protein signaling identified in a high-throughput cell-based calcium signaling assay. Cell Signal 2013;25(12):2848-55
- Xia M, Guo V, Huang R, et al. Inhibition of morphine-induced camp overshoot: a cell-based assay model in a high-throughput format. Cell Mol Neurobiol 2011;31(6):901-7
- Brothers SP, Saldanha SA, Spicer TP, et al. Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening. Mol Pharmacol 2010;77(1):46-57
- Belfer I, Hipp H, Bollettino A, et al. Alcoholism is associated with galr3 but not two other galanin receptor genes. Genes Brain Behav 2007;6(5):473-81
- Robinson J, Smith A, Sturchler E, et al. Development of a high-throughput screening-compatible cell-based functional assay to identify small molecule probes of the galanin 3 receptor (galr3). Assay Drug Dev Technol 2013;11(8):468-77
- Holmes A, Picciotto MR. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction? CNS Neurol Disord Drug Targets 2006;5(2):225-32
- Cannella N, Kallupi M, Ruggeri B, et al. The role of the neuropeptide s system in addiction: Focus on its interaction with the crf and hypocretin/orexin neurotransmission. Prog Neurobiol 2013;100:48-59
- Marugan J, Liu K, Zheng W, et al. Identification of functionally selective small molecule antagonists of the neuropeptide-s receptor: naphthopyranopyrimidines. In: Probe reports from the nih molecular libraries program. National Institutes of Health, Bethesda, MD; 2010
- Ashare RL, Schmidt HD. Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov 2014;9(6):579-94
- Perrey DA, German NA, Gilmour BP, et al. Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor. J Med Chem 2013;56(17):6901-16
- Parajuli B, Kimble-Hill AC, Khanna M, et al. Discovery of novel regulators of aldehyde dehydrogenase isoenzymes. Chem Biol Interact 2011;191(1-3):153-8
- Koppaka V, Thompson DC, Chen Y, et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev 2012;64(3):520-39
- Available from: https://pubchem.Ncbi.Nlm.Nih.Gov/assay/assay.Cgi?Aid=1030
- Zielinski T, Kimple AJ, Hutsell SQ, et al. Two galpha(i1) rate-modifying mutations act in concert to allow receptor-independent, steady-state measurements of rgs protein activity. J Biomol Screen 2009;14(10):1195-206
- Traynor J. Regulator of g protein-signaling proteins and addictive drugs. Ann N Y Acad Sci 2010;1187(1):341-52
- Available from: https://pubchem.Ncbi.Nlm.Nih.Gov/assay/assay.Cgi?Aid=504845
- Monroy CA, Mackie DI, Roman DL. A high throughput screen for rgs proteins using steady state monitoring of free phosphate formation. PLoS One 2013;8(4):e62247
- Wang Y, Cesena TI, Ohnishi Y, et al. Small molecule screening identifies regulators of the transcription factor delta fosb. ACS Chem Neurosci 2012;3(7):546-56
- Glass MJ. Opioid dependence and nmda receptors. Ilar J 2011;52:342-51
- Collier AD, Khan KM, Caramillo EM, et al. Zebrafish and conditioned place preference: A translational model of drug addiction. Prog Neuropsychopharmacol Biol Psychiatry 2014. [Epub ahead of print]
- Stewart A, Wong K, Cachat J, et al. Zebrafish models to study drug abuse-related phenotypes. Rev Neurosci 2011;22(1):95-105
- Kalueff AV, Stewart AM, Gerlai R. Zebrafish as an emerging model for studying complex brain disorders. Trends Pharmacol Sci 2014;35(2):63-75
- Giacomotto J, Segalat L. High-throughput screening and small animal models, where are we? Br J Pharmacol 2010;160(2):204-16
- Wielhouwer EM, Ali S, Al-Afandi A, et al. Zebrafish embryo development in a microfluidic flow-through system. Lab Chip 2011;11(10):1815-24
- Mathias JR, Saxena MT, Mumm JS. Advances in zebrafish chemical screening technologies. Future Med Chem 2012;4(14):1811-22
- Stewart AM, Braubach O, Spitsbergen J, et al. Zebrafish models for translational neuroscience research: from tank to bedside. Trends Neurosci 2014;37(5):264-78
- Cavodeassi F, Bene FD, Fürthauer M, et al. Report of the second european zebrafish principal investigator meeting in karlsruhe, germany, march 21–24, 2012. Zebrafish 2013;10(1):119-23
- Neelkantan N, Mikhaylova A, Stewart AM, et al. Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds. ACS Chem Neurosci 2013;4(8):1137-50
- Cousin MA, Ebbert JO, Wiinamaki AR, et al. Larval zebrafish model for fda-approved drug repositioning for tobacco dependence treatment. PLoS One 2014;9(3):e90467
- Yozzo KL, Isales GM, Raftery TD, Volz DC. High-content screening assay for identification of chemicals impacting cardiovascular function in zebrafish embryos. Environ Sci Technol 2013;47(19):11302-10
- Huang HG, Lindgren A, Wu XR, et al. High-throughput screening for bioactive molecules using primary cell culture of transgenic zebrafish embryos. Cell Rep 2012;2(3):695-704
- Tran TC, Sneed B, Haider J, et al. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res 2007;67(23):11386-92
- Gasque G, Conway S, Huang J, et al. Small molecule drug screening in drosophila identifies the 5ht2a receptor as a feeding modulation target. Sci Rep 2013;3(2120):1-8
- Becnel J, Johnson O, Majeed ZR, et al. Dreadds in drosophila: a pharmacogenetic approach for controlling behavior, neuronal signaling, and physiology in the fly. Cell Rep 2013;4(5):1049-59
- O’Reilly LP, Luke CJ, Perlmutter DH, et al. C. Elegans in high-throughput drug discovery. Adv Drug Deliv Rev 2014;2014(69-70):247-53
- Hanks JB, Gonzalez-Maeso J. Animal models of serotonergic psychedelics. ACS Chem Neurosci 2013;4(1):33-42
- Tecott LH, Nestler EJ. Neurobehavioral assessment in the information age. Nat Neurosci 2004;7(5):462-6
- Kafkafi N, Mayo CL, Elmer GI. Mining mouse behavior for patterns predicting psychiatric drug classification. Psychopharmacology (Berl) 2014;231(1):231-42
- Portal E, Riess O, Nguyen HP. Automated home cage assessment shows behavioral changes in a transgenic mouse model of spinocerebellar ataxia type 17. Behav Brain Res 2013;250:157-65
- Lipp H-P. High-throughput and automated behavioural screening of normal and genetically modified mice. Bus Brief Future Drug Discov 2005;8:1-5
- Brodkin J, Frank D, Grippo R, et al. Validation and implementation of a novel high-throughput behavioral phenotyping instrument for mice. J Neurosci Methods 2014;224:48-57
- Moreno AY, Janda KD. Current challenges for the creation of effective vaccines against drugs of abuse. Expert Rev Vaccines 2011;10(12):1637-9
- Shen XY, Kosten TR. Immunotherapy for drug abuse. CNS Neurol Disord Drug Target 2011;10(8):876-9
- Chi KR. Vaccines move forward against a range of addictions. Nat Med 2011;17(2):146
- Hipser C, Bushlin I, Gupta A, et al. Role of antibodies in developing drugs that target g-protein-coupled receptor dimers. Mt Sinai J Med 2010;77(4):374-80
- Pentel P, Lesage M. New directions in nicotine vaccine design and use. Adv Pharmacol 2013;69:553-80
- Miller ML, Moreno AY, Aarde SM, et al. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry 2013;73(8):721-8
- Brimijoin S, Shen XY, Orson F, Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines 2013;12(3):323-32
- Shen XY, Orson FM, Kosten TR. Vaccines against drug abuse. Clin Pharmacol Ther 2012;91(1):60-70
- Carrera MR, Ashley JA, Zhou B, et al. Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci USA 2000;97(11):6202-6
- Carrera MR, Ashley JA, Wirsching P, et al. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA 2001;98(4):1988-92
- Bazan J, Calkosinski I, Gamian A. Phage display – a powerful technique for immunotherapy: 2. Vaccine delivery. Hum Vaccin Immunother 2012;8(12):1829-35
- Mathews Griner LA, Guha R, Shinn P, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated b-cell-like diffuse large b-cell lymphoma cells. Proc Natl Acad Sci USA 2014;111(6):2349-54
- Sekhon BS. Repositioning drugs and biologics: Retargeting old/existing drugs for potential new therapeutic applications. J Pharm Educ Res 2013;4(1):1
- Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci 2011;12(11):623-37
- Nestler EJ. Epigenetic mechanisms of drug addiction. Neuropharmacology 2014;76(Pt B):259-68
- Tuesta LM, Zhang Y. Mechanisms of epigenetic memory and addiction. Embo J 2014;33(10):1091-103
- Available from: http://www.Nimh.Nih.Gov/about/organization/dnbbs/molecular-cellular-and-genomic-neuroscience-research-branch/molecular-pharmacology-research-program.Shtml
- Available from: http://pdsp.Med.Unc.Edu/indexr.Html
- Available from: http://www.Nature.Com/news/2009/091101/full/news.2009.1047.Html
- Kupferschmidt K. High hopes. Science 2014;345(6192):18-23
- Tagliazucchi E, Carhart-Harris R, Leech R, et al. Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp 2014. [Epub ahead of print]
- Kupferschmidt K. Can ecstasy treat the agony of ptsd? Science 2014;345(6192):22-3
- Huang R, Southall N, Wang Y, et al. The ncgc pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 2011;3(80):80ps16
- Available from: http://www.Unodc.Org/documents/scientific/nps_2013_smart.Pdf
- Available from: http://www.Economist.Com/news/international/21602729-traditional-drugs-lose-their-lure-novel-ones-are-filling-gap-market-new
- Westwell AD, Caldicott DG, Hutchings A. The dark side of pharmaceutical chemistry. Future Med Chem 2012;4(2):129-32
- Nichols D. Legal highs: the dark side of medicinal chemistry. Nature 2011;469(7328):7
- Appendino G, Minassi A, Taglialatela-Scafati O. Recreational drug discovery: Natural products as lead structures for the synthesis of smart drugs. Nat Prod Rep 2014;31(7):880-904
- Gentry PR, Bridges TM, Lamsal A, et al. Discovery of ml326: the first sub-micromolar, selective m5 pam. Bioorg Med Chem Lett 2013;23(10):2996-3000
- Frankowski KJ, Hedrick MP, Gosalia P, et al. Discovery of small molecule kappa opioid receptor agonist and antagonist chemotypes through a hts and hit refinement strategy. ACS Chem Neurosci 2012;3(3):221-36
- Diaz JL, Christmann U, Fernandez A, et al. Synthesis and biological evaluation of a new series of hexahydro-2h-pyrano[3,2-c]quinolines as novel selective sigma1 receptor ligands. J Med Chem 2013;56(9):3656-65